An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioen

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Drug: CNMAu8
Sponsors: Clene Nanomedicine
Active, not recruiting

Lue lisää...